The effects of atorvastatin on the kidney injury in mice with pulmonary fibrosis.
J Pharm Pharmacol
; 71(8): 1301-1310, 2019 Aug.
Article
en En
| MEDLINE
| ID: mdl-31215034
ABSTRACT
OBJECTIVES:
The present study investigated the effects of atorvastatin on kidney injury in mice with pulmonary fibrosis (PF).METHODS:
Adult mice were divided into four groups mice treated with intratracheal bleomycin (I) and their controls (II), and mice treated with atorvastatin for 10 days after 7 days from bleomycin treatment (III) and their controls (IV). Mice were dissected on the 21st day. KEYFINDINGS:
Mononuclear cell infiltrations, injured proximal tubule epithelium and p-c-Jun level increased, while cell proliferation and the levels of p-SMAD2, ELK1, p-ELK1, p-ATF2 and c-Jun decreased in the kidney tissue of mice with PF. The atorvastatin treatments to mice with PF resulted in significant increases at the TGF-ß activation, cell proliferation and kidney damage and decreases in the levels of p-SMAD2, p-ELK1, p-ATF2 and p-c-Jun, but not change the p-SMAD3, ELK1 and ATF2 in kidneys.CONCLUSIONS:
The depletion of MAPK signals, rather than SMAD signalling, is effective in kidney damage of mice with PF. Atorvastatin did not regress kidney damage in these mice, whereas it increases the kidney injury. The c-Jun-mediated JNK signals could help kidney repair through cell proliferation. The treatment time and doses of atorvastatin should be optimized for regression of kidney damage.Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
Fibrosis Pulmonar
/
Atorvastatina
/
Riñón
/
Enfermedades Renales
Tipo de estudio:
Prognostic_studies
Límite:
Animals
Idioma:
En
Revista:
J Pharm Pharmacol
Año:
2019
Tipo del documento:
Article
País de afiliación:
Turquía